XML 44 R34.htm IDEA: XBRL DOCUMENT
v3.21.4

Restatement (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2021
Condensed Financial Information Disclosure [Abstract] |
Schedule of balance sheet |
|  | September 30, |  |  | Restatement |  |  | September 30, |
|  | 2021 |  |  | Adjustment |  |  | 2021 |
|  | (As Reported) |  |  |  |  |  | (As Restated) |
ASSETS |  |  |  |  |  |  |  |  |
Current assets: |  |  |  |  |  |  |  |  |
Cash |  | $ | 1,082 |  |  | $ | - |  |  | $ | 1,082 |
Prepaid expenses |  |  | - |  |  |  | - |  |  |  | - |
Total current assets |  |  | 1,082 |  |  |  | - |  |  |  | 1,082 |
Total assets |  | $ | 1,082 |  |  | $ | - |  |  | $ | 1,082 |
LIABILITIES AND STOCKHOLDERS' DEFICIT |  |  |  |  |  |  |  |  |  |  |  |
Current liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Accounts payable and accrued expenses |  | $ | 4,218,421 |  |  | $ | 24,400 |  |  | $ | 4,242,821 |
Accrued payroll and related expenses |  |  | 4,037,298 |  |  |  | - |  |  |  | 4,037,298 |
Deferred revenue |  |  | 25,000 |  |  |  | - |  |  |  | 25,000 |
Advances |  |  | 122,000 |  |  |  | - |  |  |  | 122,000 |
Non-convertible notes payable, current portion, net of debt discount of $15,862 and $0, respectively |  |  | 1,759,589 |  |  |  | 493 |  |  |  | 1,760,082 |
Derivative liabilities |  |  | 4,289,634 |  |  |  | - |  |  |  | 4,289,634 |
Convertible notes payable |  |  | 3,063,970 |  |  |  | - |  |  |  | 3,063,970 |
Total current liabilities |  |  | 17,515,912 |  |  |  | 24,893 |  |  |  | 17,540,805 |
Non-convertible notes payable, net of debt discount of $1,636 and $0, respectively |  |  | 128,857 |  |  |  | (493 | ) |  |  | 128,364 |
PPP note payable |  |  | - |  |  |  | - |  |  |  | - |
Total liabilities |  |  | 17,644,769 |  |  |  | 24,400 |  |  |  | 17,669,169 |
Commitments and contingencies (See Note 9) |  |  |  |  |  |  |  |  |  |  |  |
Stockholders' deficit: |  |  |  |  |  |  |  |  |  |  |  |
Preferred stock - 10,000,000 shares authorized: |  |  |  |  |  |  |  |  |  |  |  |
Preferred stock - Series X, $0.0001 par value, $20,000 stated value, 100 shares authorized; 26.05 and 16.05 shares issued and outstanding, respectively |  |  | - |  |  |  | - |  |  |  | - |
Preferred stock - Series Y, $0.001 par value, $20,000 stated value, 1,000 shares authorized; 720.515674 and 654.781794 shares issued; 720.515674 and 626.995464 shares outstanding, and 0 and 27.78633 to be issued, respectively |  |  | 1 |  |  |  | - |  |  |  | 1 |
Preferred stock - Series Z, $0.001 par value, $20,000 stated value, 500 shares authorized; 500 and 0 shares issued; 0 and 0 shares outstanding, and 500 and 0 to be issued, respectively |  |  | 1 |  |  |  | - |  |  |  | 1 |
Preferred stock - Series C, $0.001 par value, 1,000 shares authorized; 1,000 shares issued and outstanding |  |  | 1 |  |  |  | - |  |  |  | 1 |
Preferred stock - Series A, $0.001 par value, 6,000 shares authorized; 0 shares issued and outstanding |  |  | - |  |  |  | - |  |  |  | - |
Preferred stock - Series B, $0.001 par value, 2,000 shares authorized; 0 shares issued and outstanding |  |  | - |  |  |  | - |  |  |  | - |
Common stock, $0.001par value, 1,200,000,000 shares authorized; 499,871,337 and 493,726,405 shares issued and outstanding, respectively |  |  | 499,871 |  |  |  | - |  |  |  | 499,871 |
Common stock to be issued, 906,373,564 and 907,379,814 shares, respectively |  |  | 906,374 |  |  |  | - |  |  |  | 906,374 |
Additional paid in capital |  |  | 299,667,352 |  |  |  | 6,378,799 |  |  |  | 306,046,151 |
Discount on preferred stock |  |  | - |  |  |  | - |  |  |  | - |
Accumulated deficit |  |  | (318,717,287 | ) |  |  | (6,403,199 | ) |  |  | (325,120,486 | )
Total stockholders' deficit |  |  | (17,643,687 | ) |  |  | (24,400 | ) |  |  | (17,668,087 | )
Total liabilities and stockholders' deficit |  | $ | 1,082 |  |  | $ | - |  |  | $ | 1,082 |
Schedule of operations |
|  | Three Months Ended September 30, 2021 |  |  | Restatement Adjustment |  |  | Three Months Ended September 30, 2021 |
|  | (As Reported) |  |  |  |  |  | (As Restated) |
Revenues |  | $ | 54 |  |  | $ | - |  |  | $ | 54 |
Operating Expenses: |  |  |  |  |  |  |  |  |  |  |  |
Cost of revenues |  |  | - |  |  |  | - |  |  |  | - |
Advertising |  |  | (4,578 | ) |  |  | - |  |  |  | (4,578 | )
Payroll and related expense |  |  | 66,693 |  |  |  | - |  |  |  | 66,693 |
Other general and administrative expenses |  |  | 333,197 |  |  |  | - |  |  |  | 333,197 |
Total Operating Expenses |  |  | 395,312 |  |  |  | - |  |  |  | 395,312 |
Loss From Operations |  |  | (395,258 | ) |  |  | - |  |  |  | (395,258 | )
Other Income (Expense): |  |  |  |  |  |  |  |  |  |  |  |
Interest expense |  |  | (699,254 | ) |  |  | (479,951 | ) |  |  | (1,179,205 | )
Change in derivative liability for authorized shares shortfall |  |  | 2,641,481 |  |  |  | - |  |  |  | 2,641,481 |
Change in fair value of derivative liabilities |  |  | - |  |  |  | - |  |  |  | - |
Gain (loss) on settlement of convertible notes payable and accrued interest, warrants and accounts payable and cancelation of common shares in exchange for Series Y and Series Z preferred shares and cash |  |  | 4,332,489 |  |  |  | (5,923,248 | ) |  |  | (1,590,759 | )
Gain on forgiveness of debt |  |  | - |  |  |  | - |  |  |  | - |
Gain (loss) on conversion of convertible notes |  |  | - |  |  |  | - |  |  |  | - |
Total Other Income (Expense) |  |  | 6,274,716 |  |  |  | (6,403,199 | ) |  |  | (128,483 | )
Net Income (Loss) Before Income Taxes |  |  | 5,879,458 |  |  |  | (6,403,199 | ) |  |  | (523,741 | )
Provision for Income Taxes (Benefit) |  |  | - |  |  |  | - |  |  |  | - |
Net Income (Loss) |  |  | 5,879,458 |  |  |  | (6,403,199 | ) |  |  | (523,741 | )
Deemed dividend resulting from amortization of preferred stock discount |  |  | - |  |  |  | - |  |  |  | - |
Deemed dividend from warrant price protection |  |  | - |  |  |  | - |  |  |  | - |
Net Income (Loss) Available to Common Stockholders |  | $ | 5,879,458 |  |  | $ | (6,403,199 | ) |  | $ | (523,741 | )
Net Income (Loss) Per Common Share: |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | - |  |  | $ | - |  |  | $ | - |
Diluted |  | $ | - |  |  | $ | - |  |  | $ | - |
Weighted Average Common Shares Outstanding: |  |  |  |  |  |  |  |  |  |  |  |
Basic |  |  | 1,406,244,901 |  |  |  | - |  |  |  | 1,406,244,901 |
Diluted |  |  | 1,406,244,901 |  |  |  | - |  |  |  | 1,406,244,901 |
|  | Nine Months Ended September 30, 2021 |  |  | Restatement Adjustment |  |  | Nine Months Ended September 30, 2021 |
|  | (As Reported) |  |  |  |  |  | (As Restated) |
Revenues |  | $ | 1,660 |  |  | $ | - |  |  | $ | 1,660 |
Operating Expenses: |  |  |  |  |  |  |  |  |  |  |  |
Cost of revenues |  |  | 297 |  |  |  | - |  |  |  | 297 |
Advertising |  |  | 18,125 |  |  |  | - |  |  |  | 18,125 |
Payroll and related expense |  |  | 225,603 |  |  |  | - |  |  |  | 225,603 |
Other general and administrative expenses |  |  | 953,927 |  |  |  | - |  |  |  | 953,927 |
Total Operating Expenses |  |  | 1,197,952 |  |  |  | - |  |  |  | 1,197,952 |
Loss From Operations |  |  | (1,196,292 | ) |  |  | - |  |  |  | (1,196,292 | )
Other Income (Expense): |  |  |  |  |  |  |  |  |  |  |  |
Interest expense |  |  | (1,667,413 | ) |  |  | (492,151 | ) |  |  | (2,159,564 | )
Change in derivative liability for authorized shares shortfall |  |  | (159,633,797 | ) |  |  | - |  |  |  | (159,633,797 | )
Change in fair value of derivative liabilities |  |  | 300,885 |  |  |  | - |  |  |  | 300,885 |
Gain (loss) on settlement of convertible notes payable and accrued interest, warrants and accounts payable and cancelation of common shares in exchange for Series Y and Series Z preferred shares and cash |  |  | 179,272,324 |  |  |  | (5,911,048 | ) |  |  | 173,361,276 |
Gain on forgiveness of debt |  |  | 192,521 |  |  |  | - |  |  |  | 192,521 |
Gain (loss) on conversion of convertible notes |  |  | (880 | ) |  |  | - |  |  |  | (880 | )
Total Other Income (Expense) |  |  | 18,463,640 |  |  |  | (6,403,199 | ) |  |  | 12,060,441 |
Net Income (Loss) Before Income Taxes |  |  | 17,267,348 |  |  |  | (6,403,199 | ) |  |  | 10,864,149 |
Provision for Income Taxes (Benefit) |  |  | - |  |  |  | - |  |  |  | - |
Net Income (Loss) |  |  | 17,267,348 |  |  |  | (6,403,199 | ) |  |  | 10,864,149 |
Deemed dividend resulting from amortization of preferred stock discount |  |  | (34,798,923 | ) |  |  | - |  |  |  | (34,798,923 | )
Deemed dividend from warrant price protection |  |  | - |  |  |  | - |  |  |  | - |
Net Income (Loss) Available to Common Stockholders |  | $ | (17,531,575 | ) |  | $ | (6,403,199 | ) |  | $ | (23,934,774 | )
Net Income (Loss) Per Common Share: |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | (0.01 | ) |  | $ | (0.01 | ) |  | $ | (0.02 | )
Diluted |  | $ | (0.01 | ) |  | $ | (0.01 | ) |  | $ | (0.02 | )
Weighted Average Common Shares Outstanding: |  |  |  |  |  |  |  |  |  |  |  |
Basic |  |  | 1,405,511,082 |  |  |  | - |  |  |  | 1,405,511,082 |
Diluted |  |  | 1,405,511,082 |  |  |  | - |  |  |  | 1,405,511,082 |
Schedule of cashflows |
|  | Nine Months Ended September 30, 2021 |  |  | Restatement Adjustment |  |  | Nine Months Ended September 30, 2021 |
|  | (As Reported) |  |  |  |  |  | (As Restated) |
Cash flows from operating activities: |  |  |  |  |  |  |  |  |
Net income (loss) |  | $ | 17,267,348 |  |  | $ | (6,403,199 | ) |  | $ | 10,864,149 |
Adjustments to reconcile net income (loss) to net cash used in operating activities: |  |  |  |  |  |  |  |  |  |  |  |
Change in fair value of derivative liabilities |  |  | (300,885 | ) |  |  | - |  |  |  | (300,885 | )
Change in derivative liability for authorized shares shortfall |  |  | 159,633,797 |  |  |  | - |  |  |  | 159,633,797 |
Interest and amortization of debt discount |  |  | 1,665,813 |  |  |  | 492,151 |  |  |  | 2,157,964 |
(Gain) loss on conversion of convertible notes payable |  |  | 880 |  |  |  | - |  |  |  | 880 |
Gain on settlement of convertible notes payable and accrued interest, warrants and accounts payable and cancelation of common shares in exchange for Series Y and Series Z preferred shares and cash |  |  | (179,272,324 | ) |  |  | 5,911,048 |  |  |  | (173,361,276 | )
Gain on forgiveness of debt |  |  | (192,521 | ) |  |  | - |  |  |  | (192,521 | )
Share-based compensation |  |  | 166,855 |  |  |  | - |  |  |  | 166,855 |
Expenses paid directly by non-convertible note holder on behalf of company |  |  | - |  |  |  | 158,371 |  |  |  | 158,371 |
Changes in operating assets and liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Prepaid expenses |  |  | 97,132 |  |  |  | - |  |  |  | 97,132 |
Accounts payable and accrued expenses |  |  | 187,022 |  |  |  | - |  |  |  | 187,022 |
Accrued payroll and related expenses |  |  | 173,243 |  |  |  | - |  |  |  | 173,243 |
Deferred revenue |  |  | 25,000 |  |  |  | - |  |  |  | 25,000 |
Net cash used in operating activities |  |  | (548,640 | ) |  |  | 158,371 |  |  |  | (390,269 | )
Cash flows from financing activities: |  |  |  |  |  |  |  |  |  |  |  |
Bank overdrafts |  |  | - |  |  |  | - |  |  |  | - |
Proceeds from sale of Series X preferred shares |  |  | 200,000 |  |  |  | - |  |  |  | 200,000 |
Proceeds from issuance of convertible notes payable |  |  | - |  |  |  | - |  |  |  | - |
Proceeds from issuance of non-convertible notes payable |  |  | 1,515,424 |  |  |  | (1,158,371 | ) |  |  | 357,053 |
Repayment of non-convertible notes payable |  |  | (25,000 | ) |  |  | 25,000 |  |  |  | - |
Proceeds from advances |  |  | 53,991 |  |  |  | (25,000 | ) |  |  | 28,991 |
Repayments of advances |  |  | (20,178 | ) |  |  | - |  |  |  | (20,178 | )
Cash paid in settlement of debt and warrants |  |  | (1,176,000 | ) |  |  | 1,000,000 |  |  |  | (176,000 | )
Net cash provided by financing activities |  |  | 548,237 |  |  |  | (158,371 | ) |  |  | 389,866 |
Net decrease in cash |  |  | (403 | ) |  |  | - |  |  |  | (403 | )
Cash, beginning of period |  |  | 1,485 |  |  |  | - |  |  |  | 1,485 |
Cash, end of period |  | $ | 1,082 |  |  | $ | - |  |  | $ | 1,082 |
Supplemental disclosures of cash flow information: |  |  |  |  |  |  |  |  |  |  |  |
Cash paid during period for interest |  | $ | 1,600 |  |  | $ | - |  |  | $ | 1,600 |
Cash paid during period for taxes |  | $ | - |  |  | $ | - |  |  | $ | - |
Supplemental disclosure of non-cash investing and financing activities: |  |  |  |  |  |  |  |  |  |  |  |
Amortization of discount on preferred stock |  | $ | 34,798,923 |  |  | $ | - |  |  | $ | 34,798,923 |
Common shares issued upon conversion of convertible notes and accrued interest |  | $ | 133,002 |  |  | $ | - |  |  | $ | 133,002 |
Series Y preferred shares issued as settlement for convertible notes payable, accrued interest and warrants |  | $ | 1,314,678 |  |  | $ | - |  |  | $ | 1,314,678 |
Issuance of common shares previously to be issued |  | $ | 1,006 |  |  | $ | - |  |  | $ | 1,006 |
Common shares contributed back to the Company and promptly retired |  | $ | - |  |  | $ | - |  |  | $ | - |
Deemed dividend related to warrant price protection |  | $ | - |  |  | $ | - |  |  | $ | - |
Derivative liability recognized as debt discount on newly issued convertible notes |  | $ | - |  |  | $ | - |  |  | $ | - |
Reclassify accrued interest to convertible notes payable |  | $ | 93,685 |  |  | $ | - |  |  | $ | 93,685 |
Reduction of derivative liabilities stemming from settlement of convertible notes payable, accrued interest and warrants in exchange for Series Y preferred shares |  | $ | 4,834,911 |  |  | $ | - |  |  | $ | 4,834,911 |
Reduction of derivative liabilities stemming from settlement of convertible notes payable and accrued interest and cancelation of common shares and warrants for cash |  | $ | 169,815,037 |  |  | $ | - |  |  | $ | 169,815,037 |
Series Z preferred shares issued as equity kicker for note payable |  | $ | 387,262 |  |  | $ | 479,951 |  |  | $ | 867,213 |
Series Z preferred shares issued as part of settlement agreement |  | $ | 632,020 |  |  | $ | 5,898,848 |  |  | $ | 6,530,868 |
Expenses paid directly by non-convertible note holder on behalf of company |  | $ | - |  |  | $ | 158,371 |  |  | $ | 158,371 |
Settlement paid directly by CEO on behalf of company |  | $ | - |  |  | $ | 1,000,000 |  |  | $ | 1,000,000 |
Settlement payment made directly by CEO on behalf of company |  | $ | - |  |  | $ | 25,000 |  |  | $ | 25,000 |

X
- References No definition available. + Details
Name: | srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract
Namespace Prefix: | srt_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 3 -Paragraph i -Subsection 10 + Details
Name: | srt_ScheduleOfCondensedBalanceSheetTableTextBlock
Namespace Prefix: | srt_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 3 -Paragraph i -Subsection 10 + Details
Name: | srt_ScheduleOfCondensedCashFlowStatementTableTextBlock
Namespace Prefix: | srt_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 3 -Paragraph i -Subsection 10 + Details
Name: | srt_ScheduleOfCondensedIncomeStatementTableTextBlock
Namespace Prefix: | srt_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration